Aspire Group

Name

Aspire Group

Legal name

Aspire Lifesciences Pvt. Ltd.

Website

https://aspiregroup.co.in

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

Keywords

• Pharmaceutical manufacturing
• Contract manufacturing
• Active pharmaceutical ingredients
• Nutraceutical formulations
• Drug delivery systems

Headquarters

HQ city

Vikhroli

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Finished Formulation Sales: Sale of finished pharmaceutical, nutraceutical, biotechnological and herbal products in oral, topical and injectable forms through own marketing and co-marketing arrangements.
2. Contract Manufacturing: Development and manufacture of formulations marketed by business partners under their own trademarks and brand names. Revenue generated through manufacturing fees and long-term contract manufacturing agreements.
3. Outsourcing Services: Sourcing pharmaceutical Finished Formulations, Active Pharma Ingredients, Advanced Drug Intermediates, Specialty Chemicals, and Formulation Intermediates for worldwide pharmaceutical industry. Revenue through procurement and logistics services.
4. In-Licensing and Out-Licensing: In-licensing formulations, active ingredients and medical devices with exclusive marketing rights. Out-licensing specialty generics, super generics, and bulk drugs with customized documentation and dossiers for regulatory approvals.
5. International Market Operations: Importing, indenting, trading and exporting of fine chemicals, chemical intermediates and active ingredients through Aspire India Inc.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Aspire Group develops and markets pharmaceutical, nutraceutical, biotechnological, and herbal formulations, active pharmaceutical ingredients (APIs), formulation intermediates, and medical devices. The company delivers these offerings through contract manufacturing, in-licensing and out-licensing, global sourcing/outsourcing, and co-marketing partnerships to pharmaceutical companies worldwide. Its portfolio spans finished dosage forms across multiple therapeutic categories alongside proprietary formulation intermediates such as pellets and direct-compressible granules.

Product overview

Aspire Group is a pharmaceutical and healthcare company offering a comprehensive portfolio of products across the healthcare value chain. The company operates through its core divisions: Aspire Lifesciences Pvt. Ltd. for marketing, manufacturing, and R&D of finished formulations, active ingredients and medical devices; and Aspire India Inc. for importing, trading and exporting of fine chemicals and active ingredients. The product portfolio includes Finished Formulation Dosages (pharmaceuticals, nutraceuticals, biotechnological and herbal products in oral, topical and injectable forms), Formulation Intermediates (pellets and direct compressible granules), Active Ingredients & Intermediates, and Medical Devices & Diagnostics. The company has outsourcing capabilities for sourcing and manufacturing pharmaceutical products for global markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Finished Formulation Dosages A range of finished dosage formulations across pharmaceutical, nutraceutical, biotechnological, and herbal categories, including innovative drug delivery products, developed and manufactured for pharmaceutical company clients globally.
• Formulation Intermediates Proprietary formulation intermediates such as pellets and direct-compressible granules that serve as ready-to-use inputs for finished dosage manufacturing in client formulations.
• Active Ingredients & Intermediates Active pharmaceutical ingredients (APIs) and API intermediates produced under cGMP conditions, supplied to pharmaceutical manufacturers for use in finished formulations.
• Medical Devices & Diagnostics Medical device and diagnostic products developed and supplied as part of the company's healthcare offering to pharmaceutical and healthcare clients.
• Contract Manufacturing Services End-to-end contract manufacturing of pharmaceutical formulations and APIs for client companies, executed under WHO-GMP, USFDA, UKMHRA, TGA, EUGMP, PICS, and ANVISA compliant cGMP manufacturing environments.
• In-Licensing and Out-Licensing Services Licensing arrangements through which the company in-licenses external products for distribution/manufacture and out-licenses its own formulations, intermediates, and APIs to partner pharmaceutical companies.
• Global Sourcing and Outsourcing Services International sourcing and outsourcing services that connect clients to the company's GMP-certified global partner network for supply of pharmaceutical products across multiple geographies.

Quantifiable outcome

• Manufacturing in clean room with Class 10000 standards and sterile area with Class 100 standards at positive pressure with 30 to 40 air changes per minute.

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• WHO GMP Compliant ManufacturerscoreStrategic or Co-development PartnerAspire identifies and partners with manufacturers complying with global GMP standards including international site approvals from USFDA, EUGMP, UKMHRA, PICS, ANVISA. They assist production, logistics, and extend marketing and financial support to ensure timely deliveries at reasonable prices.
• Healthcare Companies for Co-MarketingcoreChannel Partner/ Reseller/ DistributorCo-marketing agreements with partners having strong presence and marketing expertise in specific therapy segments for products indigenously developed through stringent processes and advanced technical expertise.
• Technology Transfer PartnerscoreStrategic or Co-development PartnerPartners with advanced technical capabilities interested in sourcing, offering or jointly developing formulations, active ingredients and delivery systems or non-infringing/innovative manufacturing processes which are cost effective and patient compliant for global markets.
• In-Licensing PartnersminorStrategic or Co-development PartnerPartners seeking to strengthen their presence with specialty products for Indian market. Currently interested in in-licensing formulations, active ingredients and medical devices already marketed or in late stage clinical development in key therapy areas including Cardiology, Diabetes, Gastroenterology, Respiratory disorders, and Oncology.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Divi's Laboratories: One of India's largest API and custom synthesis manufacturers. Highly comparable as a vertically integrated Indian pharma company offering APIs and intermediates with strong regulatory clearances, but at materially greater scale than Aspire.
• Laurus Labs: Indian CDMO and API manufacturer with FDA-inspected facilities supplying finished formulations and intermediates globally. Directly comparable business model (API + formulation + contract services) and similar multi-regulatory positioning, though at far greater scale.
• Aurobindo Pharma: Large Indian generic and API manufacturer with broad therapeutic coverage including cardiology, GI and oncology. Overlaps with Aspire in therapy area breadth, API/formulation integration and export-oriented B2B model.
• Piramal Pharma Solutions: Global CDMO division of Piramal Group offering API, formulation and finished dosage contract manufacturing. Comparable contract manufacturing and licensing business model with overlapping regulatory capabilities, but at much larger scale.
• Syngene International: Indian CRO/CDMO providing contract research and manufacturing services to global pharma. Comparable contract services orientation, but with greater discovery and clinical research capability beyond Aspire's formulation focus.

Direct peers

• Aragen Life Sciences: Indian contract research and manufacturing organization (formerly GVK Biosciences) providing API process development and manufacturing services. Comparable CRO/CDMO model serving global pharma with regulatory-compliant facilities.
• Sai Life Sciences: Indian CRO/CDMO offering API development, process R&D and contract manufacturing services to global pharma. Closely matches Aspire's integrated intermediates-to-API services model and target customer profile.
• Granules India: Indian pharma manufacturer specializing in finished dosages (oral solids, pellets) and APIs with global regulatory certifications. Closely comparable in terms of finished formulation formats (pellets, granules) and contract manufacturing services.
• Neuland Laboratories: India-based CDMO focused on API development, contract manufacturing and custom synthesis. Closest direct comparable to Aspire's API and formulation intermediate business in scale, regulatory profile and B2B customer base.
• Suven Pharmaceuticals: Indian CDMO focused on API and intermediate manufacturing for global pharma customers. Similar B2B contract manufacturing model, therapeutic area focus, and reliance on regulatory-compliant facilities for market access.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/aspirelifes
• Facebookfacebook.com/AspireLifesciences
• LinkedInlinkedin.com/company/aspire-lifesciences-pvt-ltd-

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspire Group